Advertisement

Anabolic Deficiencies in Heart Failure

Ready for Prime Time?

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
        Eur Heart J. 2016; 37: 2129-2200
        • Paulus W.J.
        • Tschöpe C.
        A novel paradigm for heart failure with preserved ejection fraction.
        J Am Coll Cardiol. 2013; 62: 263-271
        • Steinberg B.A.
        • Zhao X.
        • Heidenreich P.A.
        • et al.
        Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.
        Circulation. 2012; 126: 65-75
        • Braunwald E.
        Heart failure.
        JACC Heart Fail. 2013; 1: 1-20
        • Roger V.L.
        • Weston S.A.
        • Redfield M.M.
        • et al.
        Trends in heart failure incidence and survival in a community-based population.
        JAMA. 2004; 292: 344-350
        • Benjamin E.J.
        • Muntner P.
        • Alonso A.
        • et al.
        Heart disease and stroke statistics—2019 update: a report from the American Heart Association.
        Circulation. 2019; 139: e56-e528
        • Niebauer J.
        • Pflaum C.D.
        • Clark A.L.
        • et al.
        Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation.
        J Am Coll Cardiol. 1998; 32: 393-397
        • Iervasi G.
        • Pingitore A.
        • Landi P.
        • et al.
        Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease.
        Circulation. 2003; 107: 708-713
        • Doehner W.
        • Rauchhaus M.
        • Ponikowski P.
        • et al.
        Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure.
        J Am Coll Cardiol. 2005; 46: 1019-1026
        • Marra A.M.
        • Arcopinto M.
        • Bobbio E.
        • et al.
        An unusual case of dilated cardiomyopathy associated with partial hypopituitarism.
        Intern Emerg Med. 2012; 7: S85-S87
        • Arcopinto M.
        • Salzano A.
        • Bossone E.
        • et al.
        Multiple hormone deficiencies in chronic heart failure.
        Int J Cardiol. 2015; 184: 421-423
        • Marra A.M.
        • Arcopinto M.
        • Salzano A.
        • et al.
        Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure.
        Int J Cardiol. 2016; 209: 114-117
        • Arcopinto M.
        • Salzano A.
        • Giallauria F.
        • et al.
        Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: insights from the T.O.S.CA. GHD Study.
        PLoS One. 2017; 12: e0170058
        • Jankowska E.A.
        • Biel B.
        • Majda J.
        • et al.
        Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.
        Circulation. 2006; 114: 1829-1837
        • Saccà L.
        Heart failure as a multiple hormonal deficiency syndrome.
        Circ Heart Fail. 2009; 2: 151-156
        • Salzano A.
        • Marra A.M.
        • Ferrara F.
        • et al.
        Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction.
        Int J Cardiol. 2016; 225: 1-3
        • Arcopinto M.
        • Salzano A.
        • Isgaard J.
        • et al.
        Hormone replacement therapy in heart failure.
        Curr Opin Cardiol. 2015; 30: 277-284
        • McAllister D.A.
        • Read S.H.
        • Kerssens J.
        • et al.
        Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus.
        Circulation. 2018; 138: 2774-2786
        • Suskin N.
        • McKelvie R.S.
        • Burns R.J.
        • et al.
        Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.
        Eur Heart J. 2000; 21: 1368-1375
        • Saccà L.
        • Napoli R.
        Insulin resistance in chronic heart failure: a difficult bull to take by the horns.
        Nutr Metab Cardiovasc Dis. 2009; 19: 303-305
        • Ingelsson E.
        • Sundstrom J.
        • Arnlov J.
        • et al.
        Insulin resistance and risk of congestive heart failure.
        JAMA. 2005; 294: 334-341
        • Swan J.W.
        • Anker S.D.
        • Walton C.
        • et al.
        Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.
        J Am Coll Cardiol. 1997; 30: 527-532
        • Nikolaidis L.A.
        • Elahi D.
        • Hentosz T.
        • et al.
        Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
        Circulation. 2004; 110: 955-961
        • Witteless R.M.
        • Fowler M.N.
        Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
        J Am Coll Cardiol. 2008; 51: 93-102
        • O'Connor C.M.1
        • Whellan D.J.
        • Lee K.L.
        • et al.
        Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
        JAMA. 2009; 301: 1439-1450
        • Gerstein H.C.
        • Yusuf S.
        • Bosch J.
        • et al.
        Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
        Lancet. 2006; 368: 1096-1105
        • Cittadini A.
        • Napoli R.
        • Monti M.G.
        • et al.
        Metformin prevents the development of chronic heart failure in the SHHF rat model.
        Diabetes. 2012; 201: 944-953
        • Masoudi F.A.
        • Inzucchi S.E.
        • Wang Y.
        • et al.
        Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
        Circulation. 2005; 111: 583-590
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (CHFA) of the ESC.
        Eur J Heart Fail. 2016; 18: 891-975
        • Sokos G.G.
        • Nikolaidis L.A.
        • Mankad S.
        • et al.
        Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
        J Card Fail. 2006; 12: 694-699
        • Scirica B.M.
        • Bhatt D.L.
        • Braunwald E.
        • et al.
        Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
        N Engl J Med. 2013; 369: 1317-1326
        • White W.B.
        • Cannon C.P.
        • Heller S.R.
        • et al.
        Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
        N Engl J Med. 2013; 369: 1326-1335
        • Jorsal A.
        • Kistorp C.
        • Holmager P.
        • et al.
        Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
        Eur J Heart Fail. 2017; 19: 69-77
        • Lepore J.J.
        • Olson E.
        • Demopoulos L.
        • et al.
        Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction.
        JACC Heart Fail. 2016; 4: 559-566
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2118
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 376: 644-657
        • Wiviott S.D.
        • Raz I.
        • Bonaca M.P.
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1812389
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • et al.
        Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy.
        N Engl J Med. 2019; https://doi.org/10.1056/NEJMoa1811744
        • Rossetti L.
        • Smith D.
        • Shulman G.I.
        • et al.
        Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
        J Clin Invest. 1987; 79: 1510-1515
        • Napoli R.
        • Hirshman M.F.
        • Horton E.S.
        Mechanisms and time course of impaired skeletal muscle glucose uptake in streptozocin diabetic rats.
        J Clin Invest. 1995; 95: 427-437
        • Verma S.
        • McMurray J.J.V.
        SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
        Diabetologia. 2018; 61: 2108-2117
        • Sacca` L.
        • Fazio S.
        Cardiac performance: growth hormone enters the race.
        Nat Med. 1996; 2: 29-31
        • Saccà L.
        Growth hormone therapy for heart failure: swimming against the stream.
        J Card Fail. 1999; 5: 269-275
        • Cittadini A.
        • Stromer H.
        • Katz S.E.
        • et al.
        Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation.
        Circulation. 1996; 93: 800
        • Stromer H.
        • Palmieri E.A.
        • De Groot M.C.
        • et al.
        Growth hormone- and pressure overload-induced cardiac hypertrophy evoke different responses to ischemia-reperfusion and mechanical stretch.
        Growth Horm IGF Res. 2006; 16: 29-40
        • Bruel A.
        • Oxlund H.
        The effect of growth hormone on rat myocardial collagen.
        Growth Horm IGF Res. 1999; 9: 123-130
        • Cittadini A.
        • Grossman J.D.
        • Napoli R.
        • et al.
        Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction.
        J Am Coll Cardiol. 1997; 29: 1109-1116
        • D'Assante R.
        • Napoli R.
        • Salzano A.
        • et al.
        Human heart shifts from IGF-1 production to utilization with chronic heart failure.
        Endocrine. 2019; https://doi.org/10.1007/s12020-019-01993-y
        • Boger R.H.
        Role of nitric oxide in the haemodynamic effects of growth hormone.
        Growth Horm IGF Res. 1998; 8: 163-165
        • Merola B.
        • Longobardi S.
        • Sofia M.
        • et al.
        Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months’ growth hormone replacement therapy.
        Eur J Endocrinol. 1996; 135: 553-558
        • Napoli R.
        • Guardasole V.
        • Matarazzo M.
        • et al.
        Growth hormone corrects vascular dysfunction in patients with chronic heart failure.
        J Am Coll Cardiol. 2002; 39: 90-99
        • Napoli R.
        • Guardasole V.
        • Angelini V.
        • et al.
        Acute effects of growth hormone on vascular function in human subjects.
        J Clin Endocrinol Metab. 2003; 88: 2817-2820
        • Cittadini A.
        • Ishiguro Y.
        • Stromer H.
        • et al.
        Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2þ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.
        Circ Res. 1998; 83: 50-59
        • Napoli R.
        • Cittadini A.
        • Chow J.C.
        • et al.
        Chronic growth hormone treatment in normal rats reduces post-prandial skeletal muscle plasma membrane GLUT1 content, but not glucose transport or GLUT4 expression and localization.
        Biochem J. 1996; 315: 959-963
        • Cittadini A.
        • Saldamarco M.
        • Marra A.M.
        • et al.
        Growth hormone in patients with chronic heart failure and beneficial effects of its correction.
        J Clin Endocrinol Metab. 2009; 94: 3329-3336
        • Broglio F.
        • Benso A.
        • Gottero C.
        • et al.
        Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine.
        Eur J Endocrinol. 2000; 142: 157-163
        • Broglio F.
        • Fubini A.
        • Morello M.
        • et al.
        Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
        Clin Endocrinol (Oxf). 1999; 50: 417-430
        • Saccà L.
        • Napoli R.
        • Cittadini A.
        Growth hormone, acromegaly, and heart failure: an intricate triangulation.
        Clin Endocrinol (Oxf). 2003; 59: 660-671
        • Mann D.L.
        • Bristow M.R.
        Mechanisms and models in heart failure. The biomechanical model and beyond.
        Circulation. 2005; 111: 2837-2849
        • Colao A.
        The GH-IGF-I axis and the cardiovascular system: clinical implications.
        Clin Endocrinol (Oxf). 2008; 69: 347-358
        • Rosen T.
        • Bengtsson B.A.
        Premature mortality due to cardiovascular disease in hypopituitarism.
        Lancet. 1990; 336: 285-288
        • Saccà L.
        Growth hormone: a newcomer in cardiovascular medicine.
        Cardiovasc Res. 1997; 36: 3-9
        • Colao A.
        • Di Somma C.
        • Cuocolo A.
        • et al.
        The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study.
        J Clin Endocrinol Metab. 2004; 89: 5998-6004
        • Juul A.
        • Scheike T.
        • Davidsen M.
        • et al.
        Low serum insulin-like growth factor 1 is associated with increased risk of ischemic heart disease: a population-based case-control study.
        Circulation. 2002; 106: 939-944
        • Vasan R.S.
        • Sullivan L.M.
        • D’Agostino R.B.
        • et al.
        Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study.
        Ann Intern Med. 2003; 139: 642-648
        • Laughlin G.A.
        • Barrett-Connor E.
        • Criqui M.H.
        • et al.
        The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study.
        J Clin Endocrinol Metab. 2004; 89: 114-120
        • Anker S.D.
        • Chua T.P.
        • Ponikowski P.
        • et al.
        Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance for cardiac cachexia.
        Circulation. 1997; 96: 526-534
        • Al-Obaidi M.K.
        • Hon J.F.K.
        • Stubbs P.J.
        • et al.
        Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure.
        Am Heart J. 2001; 142: e10
        • Anwar A.
        • Gaspoz J.M.
        • Pampallona S.
        • et al.
        Effect of congestive heart failure on the insulin-like growth factor-1 system.
        Am J Cardiol. 2002; 90: 1402-1405
        • Andreassen M.
        • Caroline Kistorp C.
        • Raymond I.
        • et al.
        Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure.
        Growth Horm IGF Res. 2009; 19: 486-490
        • Petretta M.
        • Colao A.
        • Sardu C.
        • et al.
        NT-proBNP, IGF-I and survival in patients with chronic heart failure.
        Growth Horm IGF Res. 2007; 17: 288-296
        • Yang R.
        • Bunting S.
        • Gillett N.
        • et al.
        Growth hormone improves cardiac performance in experimental heart failure.
        Circulation. 1995; 92: 262-267
        • Duerr R.L.
        • McKirnan M.D.
        • Gim R.D.
        • et al.
        Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat.
        Circulation. 1996; 93: 2188-2196
        • Ryoke T.
        • Gu Y.
        • Mao L.
        • et al.
        Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition.
        Circulation. 1999; 100: 1734-1740
        • Fazio S.
        • Sabatini D.
        • Capaldo B.
        • et al.
        A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.
        N Engl J Med. 1996; 334: 809-814
        • Frustaci A.
        • Gentiloni N.
        • Russo M.A.
        Growth hormone in the treatment of dilated cardiomyopathy.
        N Engl J Med. 1996; 335: 672-673
        • Genth-Zotz S.
        • Zotz R.
        • Geil S.
        • et al.
        Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity.
        Circulation. 1999; 99: 18-21
        • Isgaard J.
        • Bergh C.H.
        • Caidahl K.
        • et al.
        A placebo-controlled study of growth hormone in patients with congestive heart failure.
        Eur Heart J. 1998; 19: 1704-1711
        • Osterziel K.J.
        • Strohm O.
        • Schuler J.
        • et al.
        Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
        Lancet. 1998; 351: 1233-1237
        • Jose V.J.
        • Zechariah T.U.
        • George P.
        • et al.
        Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study.
        Indian Heart J. 1999; 51: 183-185
        • Smit J.W.
        • Janssen Y.J.
        • Lamb H.J.
        • et al.
        Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass.
        J Clin Endocrinol Metab. 2001; 86: 4638-4643
        • Spallarossa P.
        • Rossettin P.
        • Minuto F.
        • et al.
        Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.
        Am J Cardiol. 1999; 84: 430-433
        • Perrot A.
        • Ranke M.B.
        • Dietz R.
        • et al.
        Growth hormone treatment in dilated cardiomyopathy.
        J Card Surg. 2001; 16: 127-131
        • Acevedo M.
        • Corbalan R.
        • Chamorro G.
        • et al.
        Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status.
        Int J Cardiol. 2003; 87: 185-191
        • Adamopoulos S.
        • Parissis J.T.
        • Paraskevaidis I.
        • et al.
        Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy.
        Eur Heart J. 2003; 24: 2186-2196
        • Cittadini A.
        • Ines Comi L.
        • Longobardi S.
        • et al.
        A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies.
        Eur Heart J. 2003; 24: 664-672
        • Le Corvoisier P.
        • Hittinger L.
        • Chanson P.
        • et al.
        Cardiac effects of growth hormone treatment in chronic heart failure: a metanalysis.
        J Clin Endocrinol Metab. 2007; 92: 180-185
        • Tritos N.A.
        • Danias P.G.
        Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis.
        Endocr Pract. 2008; 14: 40-49
        • Cittadini A.
        • Marra A.
        • Arcopinto M.
        • et al.
        Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency.
        JACC Heart Fail. 2013; 1: 325-330
        • Khaw K.T.
        • Dowsett M.
        • Folkerd E.
        • et al.
        Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.
        Circulation. 2007; 116: 2694-2701
        • Criqui M.H.
        Epidemiology of atherosclerosis: an updated overview.
        Am J Cardiol. 1986; 57: 18C-23C
        • Dubey R.K.
        • Oparil S.
        • Imthurn B.
        • et al.
        Sex hormones and hypertension.
        Cardiovasc Res. 2002; 53: 688-708
        • Ng M.K.
        • Quinn C.M.
        • McCrohon J.A.
        • et al.
        Androgens up-regulate atherosclerosis- related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis.
        J Am Coll Cardiol. 2003; 42: 1306-1313
        • McCrohon J.A.
        • Jessup W.
        • Handelsman D.J.
        • et al.
        Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1.
        Circulation. 1999; 99: 2317-2322
        • Muller M.
        • van der Schouw Y.T.
        • Thijssen J.H.
        • et al.
        Endogenous sex hormones and cardiovascular disease in men.
        J Clin Endocrinol Metab. 2003; 88: 5076-5086
        • Adams M.R.
        • Williams J.K.
        • Kaplan J.R.
        Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness.
        Arterioscler Thromb Vasc Biol. 1995; 15: 562-570
        • Mäkinen J.
        • Järvisalo M.J.
        • Pöllänen P.
        • et al.
        Increased carotid atherosclerosis in andropausal middle-aged men.
        J Am Coll Cardiol. 2005; 45: 1603-1608
        • Haring R.
        • Völzke H.
        • Steveling A.
        • et al.
        Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79.
        Eur Heart J. 2010; 31: 1494-1501
        • Laughlin G.A.
        • Barrett-Connor E.
        • Bergstrom J.
        Low serum testosterone and mortality in older men.
        J Clin Endocrinol Metab. 2008; 93: 68-75
        • Malkin C.J.
        • Pugh P.J.
        • Morris P.D.
        • et al.
        Low serum testosterone and increased mortality in men with coronary heart disease.
        Heart. 2010; 96: 1821-1825
        • Komesaroff P.A.
        Unravelling the enigma of dehydroepiandrosterone: moving forward step by step.
        Endocrinology. 2008; 149: 886-888
        • Tivesten A.
        • Vandenput L.
        • Carlzon D.
        • et al.
        Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men.
        J Am Coll Cardiol. 2014; 64: 1801-1810
        • Marsh J.D.
        • Lehmann M.H.
        • Ritchie R.H.
        • et al.
        Androgen receptors mediate hypertrophy in cardiac myocytes.
        Circulation. 1998; 98: 256-261
        • Golden K.L.
        • Marsh J.D.
        • Jiang Y.
        • et al.
        Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes.
        Am J Physiol Endocrinol Metab. 2003; 285: E449-E453
        • Golden K.L.
        • Marsh J.D.
        • Jiang Y.
        • et al.
        Gonadectomy alters myosin heavy chain composition in isolated cardiac myocytes.
        Endocrine. 2004; 24: 137-140
        • Liu P.Y.
        • Death A.K.
        • Handelsman D.J.
        Androgens and cardiovascular disease.
        Endocr Rev. 2003; 24: 313-340
        • Ikeda Y.
        • Aihara K.
        • Yoshida S.
        • et al.
        Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling.
        Endocrinology. 2009; 150: 2857-2864
        • Lapauw B.
        • Goemaere S.
        • Zmierczak H.
        • et al.
        The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes.
        Eur J Endocrinol. 2008; 159: 459-468
        • Kaufman J.M.
        • Vermeulen A.
        The decline of androgen levels in elderly men and its clinical and therapeutic implications.
        Endocr Rev. 2005; 26: 833-876
        • Moriyama Y.
        • Yasue H.
        • Yoshimura M.
        • et al.
        The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity.
        J Clin Endocrinol Metab. 2000; 85: 1834-1840
        • Kontoleon P.E.
        • Anastasiou-Nana M.I.
        • Papapetrou P.D.
        • et al.
        Hormonal profile in patients with congestive heart failure.
        Int J Cardiol. 2003; 87: 179-183
        • Malkin C.J.
        • Jones T.H.
        • Channer K.S.
        Testosterone in chronic heart failure.
        Front Horm Res. 2009; 37: 183-196
        • Iellamo F.
        • Rosano G.
        • Volterrani M.
        Testosterone deficiency and exercise intolerance in heart failure: treatment implications.
        Curr Heart Fail Rep. 2010; 7: 59-65
        • Pugh P.J.
        • Jones R.D.
        • West J.N.
        • et al.
        Testosterone treatment for men with chronic heart failure.
        Heart. 2004; 90: 446-447
        • Malkin C.J.
        • Channer K.S.
        • Jones T.H.
        Testosterone and heart failure.
        Curr Opin Endocrinol Diabetes Obes. 2010; 17: 262-268
        • Volterrani M.
        • Rosano G.
        • Iellamo F.
        Testosterone and heart failure.
        Endocrine. 2012; 42: 272-277
        • Nahrendorf M.
        • Frantz S.
        • Hu K.
        • et al.
        Effect of testosterone on post-myocardial infarction remodeling and function.
        Cardiovasc Res. 2003; 57: 370-378
        • Tsang S.
        • Wu S.
        • Liu J.
        • et al.
        Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation.
        Br J Pharmacol. 2008; 153: 693-709
        • Pugh P.J.
        • Jones T.H.
        • Channer K.S.
        Acute haemodynamic effects of testosterone administration in men with heart failure.
        Eur Heart J. 2002; 23: 28
        • Malkin C.J.
        • Pugh P.J.
        • West J.N.
        • et al.
        Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.
        Eur Heart J. 2006; 27: 57-64
        • Mirdamadi A.
        • Garakyaraghi M.
        • Pourmoghaddas A.
        • et al.
        Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.
        Biomed Res Int. 2014; 39: 24-32
        • Caminiti G.
        • Volterrani M.
        • Iellamo F.
        • et al.
        Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study.
        J Am Coll Cardiol. 2009; 54: 919-927
        • Stout M.
        • Tew G.A.
        • Doll H.
        • et al.
        Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.
        Am Heart J. 2012; 164: 893-901
        • Iellamo F.
        • Volterrani M.
        • Caminiti G.
        • et al.
        Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.
        J Am Coll Cardiol. 2010; 56: 1310-1316
        • Napoli R.
        • Guardasole V.
        • Angelini V.
        • et al.
        Acute effects of triiodothyronine on endothelial function in human subjects.
        J Clin Endocrinol Metab. 2007; 92: 250-254
        • Napoli R.
        • Guardasole V.
        • Zarra E.
        • et al.
        Impaired endothelial- and nonendothelial-mediated vasodilation in patients with acute or chronic hypothyroidism.
        Clin Endocrinol (Oxf). 2010; 72: 107-111
        • Napoli R.
        • Biondi B.
        • Guardasole V.
        • et al.
        Impact of hyperthyroidism and its correction on vascular reactivity in humans.
        Circulation. 2001; 104: 3076-3080
        • Klein I.
        • Danzi S.
        Thyroid disease and the heart.
        Circulation. 2007; 116: 1725-1735
        • Biondi B.
        • Fazio S.
        • Palmieri E.A.
        • et al.
        Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism.
        J Clin Endocrinol Metab. 1999; 84: 2064-2067
        • Iervasi G.
        • Molinaro S.
        • Landi P.
        • et al.
        Association between increased mortality and mild thyroid dysfunction in cardiac patients.
        Arch Intern Med. 2007; 167: 1526-1532
        • Moruzzi P.
        • Doria E.
        • Agostoni P.G.
        Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy.
        Am J Med. 1996; 101: 461-467
        • Malik F.S.
        • Mehra M.R.
        • Uber P.A.
        • et al.
        Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock.
        J Card Fail. 1999; 5: 31-37
        • Pingitore A.
        • Galli E.
        • Barison A.
        • et al.
        Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study.
        J Clin Endocrinol Metab. 2008; 93: 1351-1358
        • Salzano A.
        • D'Assante R.
        • Lander M.
        • et al.
        Hormonal replacement therapy in heart failure: focus on growth hormone and testosterone.
        Heart Fail Clin. 2019; 15: 377-391
        • Salzano A.
        • Cittadini A.
        • Bossone E.
        • et al.
        Multiple hormone deficiency syndrome: a novel topic in chronic heart failure.
        Future Sci OA. 2018; 4: FSO311
        • Salzano A.
        • Marra A.M.
        • D'Assante R.
        • et al.
        Growth hormone therapy in heart failure.
        Heart Fail Clin. 2018; 14: 501-515
        • Bossone E.
        • Arcopinto M.
        • Iacoviello M.
        • et al.
        Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry.
        Intern Emerg Med. 2018; 13: 661-671